Molecular Imaging in Gynecology: Beyond Cancer

Joni Sebastiano, Cindy Rodriguez, Zachary V Samuels, Kristen Pepin, Brian M Zeglis
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024 · vol. 65(7) , pp. 998–1003 · doi:10.2967/jnumed.124.267546 · PMID:38871386 · PMC11218728 · W4399622160
review OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review examines recent advances in PET, SPECT, MRI, and fluorescence imaging for diagnosing and managing benign gynecological conditions, highlighting needs and opportunities for growth.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Gynecological pathologies account for approximately 4.5% of the overall global disease burden. Although cancers of the female reproductive system have understandably been the focus of a great deal of research, benign gynecological conditions-such as endometriosis, polycystic ovary syndrome, and uterine fibroids-have remained stubbornly understudied despite their astonishing ubiquity and grave morbidity. This historical inattention has frequently become manifested in flawed diagnostic and treatment paradigms. Molecular imaging could be instrumental in improving patient care on both fronts. In this Focus on Molecular Imaging review, we will examine recent advances in the use of PET, SPECT, MRI, and fluorescence imaging for the diagnosis and management of benign gynecological conditions, with particular emphasis on recent clinical reports, areas of need, and opportunities for growth.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Molecular Imaging Molecular Imaging Molecular Imaging Molecular Imaging Molecular Imaging Molecular Imaging Molecular Imaging Female Female Female Female Female Gynecology Gynecology Gynecology Gynecology Gynecology Humans Humans Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (56)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-31T00:32:32.879816+00:00
License: CC0 · commercial use OK